Bleeding and New Cancer Diagnosis in Patients with Atherosclerosis: COMPASS Trial

Join Professor John Camm and Professor John Eikelboom in their discussion of the association between bleeding occurrence and new cancer diagnosis among patients with atherosclerosis receiving antithrombotic therapy.

Register for the webinar

Speaker

Professor John Eikelboom

McMaster University

Ontario, Canada

Topic

The COMPASS trial, involving over 27,000 patients, investigated whether rivaroxaban alone or rivaroxaban in combination with aspirin, would be more effective than aspirin alone for secondary cardiovascular prevention in patients with stable atherosclerotic vascular disease. Additionally, the association between bleeding occurrence and new cancer diagnosis in these patients was evaluated, which is what this 30-minute journal club explores and discusses.

View abstract Access full paper

Register your email and provide your feedback

To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey
  • Target audience

    This educational activity is designed for hospitalists, oncologists, haematologists, interventional cardiologists, internists/physicians, surgeons, and any other healthcare professional with an interest or role in the management of patients on anticoagulation.

  • Learning objectives

    After completing this educational activity, participants should be able to:

    • Describe the association between gastrointestinal and genitourinary bleeding, and new cancer diagnosis, among patients with atherosclerosis receiving antithrombotic therapy
    • Recall the clinical implications of gastrointestinal and genitourinary bleeding in patients treated with antithrombotic therapy
  • Disclosures

    Prof John Camm

    • Advisor for: Boehringer Ingelheim, Daiichi Sankyo
    • Consultant (retained) for: Boehringer Ingelheim
    • Received honoraria from: Bayer, Daiichi Sankyo, BMS-Pfizer

    John Eikelboom

    • Consulting fees and/or honoraria received from: Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myer-Squibb, Daiichi-Sankyo, Eli-Lilly, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis
    • Grants and/or in-kind support received from: Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myer-Squibb, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis

    Staff and reviewer disclosures

    PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

  • Funding

    This independent educational activity is supported by funding from Portola Pharmaceuticals Inc.
    PCM Scientific is the medical education company acting as scientific secretariat and organiser for this
    programme. The activity is run independently of the financial supporter and all content is created by
    the faculty. No funder has had input into the content of the activity.